Kerckhoff Klinik

Running trials

• Not yet recruiting

  Validation Of anatomY-specific Aortic Valve Implantation Guided by Software Using EncantoR

  NCT07696182· Abbott Medical Devices· Source

• Recruiting

  BIO|STREAM.CSP Study

  NCT07393009· Biotronik SE & Co. KG· Source

• Recruiting

  Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure

  NCT07038356· Phase 3· Christian Schulze· Source

• Recruiting

  Left Bundle Branch Area Pacing (LBBAP) PMCF Study

  NCT07217392· Abbott Medical Devices· Source

• Active, not recruiting

  REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure

  NCT06557798· The Leeds Teaching Hospitals NHS Trust· Source

• Recruiting

  Cyclosporine In Takotsubo Syndrome

  NCT05946772· Phase 2· University Hospital Heidelberg· Source

• Recruiting

  Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

  NCT06736574· Phase 3· Cytokinetics· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared with Placebo Added to Standard of Care in Adult Participants with Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

  2023-504022-19-01· Phase 3· AstraZeneca AB· Source

• Recruiting

  Prospective WCD Post CABG Registry (CABG Registry)

  NCT06570902· Zoll Medical Corporation· Source

• Recruiting

  Impact of Beta-blocker on Outcome Among Patients Undergoing Transcatheter Aortic Valve Replacement (B-TAVR)

  NCT06472934· Phase 4· University Hospital, Basel, Switzerland· Source

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Eli Lilly and Company· Source

• Enrolling by invitation

  ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation

  NCT05932615· Abbott Medical Devices· Source

• Active, not recruiting

  LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF

  NCT05983250· Phase 3· Tenax Therapeutics, Inc.· Source

• Recruiting

  Prevention Of Sudden Cardiac Death After Myocardial Infarction by Defibrillator Implantation

  NCT05665608· Charite University, Berlin, Germany· Source

• Recruiting

  Complete Revascularization Versus Culprit Lesion Only PCI in NSTEMI

  NCT05786131· Leipzig Heart Science gGmbH· Source

• Active, not recruiting

  Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

  NCT06008756· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  The ReTAVI Prospective Observational Registry

  NCT05601453· Institut für Pharmakologie und Präventive Medizin· Source

• Not yet recruiting

  First-line Cryoablation for Early Treatment of Persistent Atrial Fibrillation

  NCT05939076· Phase 3· Region Örebro County· Source

• Active, not recruiting

  Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

  NCT05701358· Population Health Research Institute· Source

• Active, not recruiting

  RESPONDER-HF Trial

  NCT05425459· Corvia Medical· Source

• Active, not recruiting

  From the Emergency Department Directly to Ablation of Atrial Fibrillation Study

  NCT05294445· Asklepios proresearch· Source

• Active, not recruiting

  A Study to Assess Disease Activity in Adult Participants With Axial Spondyloarthritis Who Receive Upadacitinib in a Real-world Setting

  NCT05094128· AbbVie· Source

• Active, not recruiting

  Evaluation of TAVR Using the NAVITOR Valve in a Global Investigation

  NCT04788888· Abbott Medical Devices· Source

• Enrolling by invitation

  Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

  NCT04848506· Phase 2/3· Cytokinetics· Source

• Active, not recruiting

  ABLATE Versus PACE: PVI or AV Node Ablation and PM Implantation for Elderly Patients With Persistent AF

  NCT04906668· St. Josefs-Hospital Wiesbaden GmbH· Source

• Recruiting

  Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

  NCT04045665· Phase 3· Icahn School of Medicine at Mount Sinai· Source

• Recruiting

  Observation of Clinical Routine Care for Patients With BIOTRONIK Implantable Cardiac Monitors (ICMs)

  NCT04075084· Biotronik SE & Co. KG· Source

• Active, not recruiting

  SyncAV Post-Market Trial

  NCT04100148· Abbott Medical Devices· Source

• Active, not recruiting

  accuRate Evaluation of Benefit With Optimal Medical Treatment With or Without Transcatheter Valve Repair of PARADOXical Low Flow Low Gradient Aortic Stenosis

  NCT03863132· IHF GmbH - Institut für Herzinfarktforschung· Source

• Active, not recruiting

  Randomized Trial of TAVI vs. SAVR in Patients With Severe Aortic Valve Stenosis at Low to Intermediate Risk of Mortality

  NCT03112980· Universitätsklinikum Hamburg-Eppendorf· Source

• Active, not recruiting

  REDUCER-I: An Observational Study of the Neovasc Reducer™ System

  NCT02710435· Shockwave Medical, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure6 recruiting
• Atrial fibrillation4 recruiting
• Aortic stenosis3 recruiting
• Coronary artery disease2 recruiting
• Stroke2 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• High blood pressure1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Myocarditis1 recruiting
• Pulmonary arterial hypertension1 recruiting

Closed trials

• Completed

  Pulsed Field or Cryoballoon Pulmonary Vein Isolation for Atrial Fibrillation in Heart Failure

  NCT07181291· St. Josefs-Hospital Wiesbaden GmbH· Source

• Not yet recruiting

  Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG

  NCT07118449· Phase 2· XyloCor Therapeutics, Inc.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

  NCT06624228· Phase 3· UCB Biopharma SRL· Source

• Completed

  A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy

  NCT05582395· Phase 3· Myokardia Inc.· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Terminated

  Immunosuppressive Treatment in Chronic Virus-Negative Inflammatory Cardiomyopathy

  NCT05570409· Phase 2/3· LMU Klinikum· Source

• Completed

  A multicenter, randomized, double-blind, placebo-controlled TRial evaluating Immunosuppressive treatment in patients with chronic virus-Negative Inflammatory cardiomyopaThY (TRINITY trial)

  2024-512451-20-00· Phase 2/3· Klinikum der Universitaet Muenchen AöR· Source

• Completed

  VALVOSOFT® Pivotal Study

  NCT05235568· Cardiawave SA· Source

• Active, not recruiting

  Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

  NCT05270668· Phase 2· Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)· Source

• Completed

  Effect of antifibrotic therapy on regression of myocardial fibrosis after transcatheter aortic valve implantation (TAVI) in aortic stenosis patients with high fibrotic burden

  2024-510869-42-00· Phase 2· Universitaetsmedizin Goettingen· Source

• Completed

  A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)

  NCT04945460· Phase 2· Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA· Source

• Completed

  Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI

  NCT04981041· Phase 4· Ludwig-Maximilians - University of Munich· Source

• Completed

  Portico Valve-in-Valve Retrospective Registry

  NCT05002088· Abbott Medical Devices· Source

• Completed

  Right Atrial Fibrosis in Pulmonary Hypertension

  NCT04663230· University of Giessen· Source

• Completed

  EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

  NCT04509674· Phase 3· Boehringer Ingelheim· Source

• Completed

  Exercise Hemodynamic, Right Ventricular Coupling and Echocardiography in Pulmonary Hypertension

  NCT04663217· University of Giessen· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Amgen· Source

• Completed

  A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM

  NCT03723655· Phase 2/3· Bristol-Myers Squibb· Source

• Completed

  Confirm Rx Insertable Cardiac Monitor SMART Registry

  NCT03505801· Abbott Medical Devices· Source

• Completed

  Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality

  NCT03036462· Phase 4· Universitätsklinikum Hamburg-Eppendorf· Source

• Completed

  Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial

  NCT02168829· Phase 4· Ottawa Heart Institute Research Corporation· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Aortic stenosis14 works · 10 trials